Research progress of anti-pulmonary fibrosis drugs targeting autotaxin-lysophosphatidic acid axis
10.16438/j.0513-4870.2023-0022
- VernacularTitle:以自分泌运动因子-溶血磷脂酸轴为靶点的抗肺纤维化药物研发进展
- Author:
Hai-yan JIANG
1
;
Lian KUANG
1
;
Tian-yu ZHOU
2
;
Hong-tao JIN
1
,
3
,
4
Author Information
1. New Drug Safety Evaluation Center, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
2. College of Pharmacy, Shaanxi University of Traditional Chinese Medicine, Xianyang 712046, China
3. NMPA Key Laboratory for Safety Research and Evaluation of Innovative Drug, Beijing 102206, China
4. Beijing Union-Genius Pharmaceutical Technology Development Co. Ltd., Beijing 100176, China
- Publication Type:Research Article
- Keywords:
autotaxin;
lysophosphatidic acid;
pulmonary fibrosis;
inhibitor
- From:
Acta Pharmaceutica Sinica
2023;57(10):2961-2969
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary fibrosis is an interstitial lung disease characterized by inflammatory injury and tissue structure destruction. Currently, there is a lack of effective therapeutic drugs for pulmonary fibrosis, and the mechanism is still unknown. Therefore, it is urgent to seek new targets for effective drugs. In pulmonary fibrosis, the level of autotaxin (ATX) in bronchoalveolar lavage fluid increases and stimulates the production of lysophosphatidic acid (LPA). The involvement of LPA receptors in activating a variety of G-protein-mediated signal transduction pathways leads to a range of related physiological effects, including pro-inflammatory signaling in epithelial cells, activation of transforming growth factor signaling, and stimulation of fibroblast accumulation. LPA receptor antagonists and ATX inhibitors have been concerned as new targets for pulmonary fiber therapy, and currently related drugs have entered clinical trials. In this paper, the pathophysiological effects of LPA and ATX in pulmonary fibrosis disease and related drug development progress were reviewed to provide reference information of new drug development for pulmonary fibrosis based on the ATX-LPA axis.
